Skip to main content
Ovarian Cancer
Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation
Read More
Ovarian Cancer
Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Long-Term Responders to Rucaparib More Likely to Have Deleterious BRCA Mutations
Read More
Ovarian Cancer
Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer
Read More
COVID-19
Potential for Anti-Cancer Agents in the Treatment of COVID-19
Read More
COVID-19
Oncology Home Infusions in the Post–COVID-19 World
Read More
Ovarian Cancer
Rucaparib As Maintenance Therapy Delays Progression in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Read More
Ovarian Cancer
Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer
Read More
Ovarian Cancer
Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer
Read More
Page 130 of 196
Results 1291 - 1300 of 1954